Noor Hisham Abdullah
Tracked across 4 events · 42 articles · First seen Mar 09, 2018 · Last active Sep 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Noor Hisham Abdullah, GSK plc's head of oncology research, expressed strong confidence in Mo-rez's blockbuster potential based on early data.
Apr 12, 2026 · 6 articles
News
Impact: Noor Hisham Abdullah, Vice Chairman and Managing Director of Emirates (airline), emphasized the long-term commitment to India and the deepening of cross-border connectivity through the acquisition.
Jun 18, 2026 · 11 articles
Business
Impact: As Vice Chairman and Managing Director of Emirates (airline), he publicly expressed confidence in Egypt's market, reinforcing the strategic rationale for the acquisition.
Mar 09, 2018 · 17 articles
Business
GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement…
Impact: Noor Hisham Abdullah, GSK's Senior Vice President and Global Head of Oncology R&D, publicly commented that the deal secures a promising T cell engager and advances GSK's leadership goals in blood cancer.
Sep 15, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Noor Hisham Abdullah live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard